medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Number 6

<< Back Next >>

Ann Hepatol 2014; 13 (6)

Chronic hepatitis C successfully treated with telaprevir, pegylated interferon and ribavirin in severe aplastic anemia

Balkan II, Bozcan S, Yemisen M, Kutlubay Z, Ozaras R

Language: English
References: 8
Page: 843-844
PDF size: 50.30 Kb.


Text Extraction

Dear Editor,

Telaprevir combination with pegylated-interferon (Peg-IFN) +ribavirin significantly improves response rates in HCV infection.1-3 However this triple regimen is particularly associated with increased rates of side effects.4 HCV infection in patients undergoing hematopoietic stem cell transplantation (HSCT) increases the risks of liver-related complications and veno-occlusive disorder.5,6 Cure of HCV before transplantation can eliminate these risks. We present a patient with severe aplastic anemia and chronic hepatitis C treated with telaprevir based triple regimen before HSCT.


REFERENCES

  1. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, et al. REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.

  2. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364(25): 2405-16. Balkan II, et al. , 2014; 13 (6): 843-844 844

  3. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, et al. PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362(14): 1292-303.

  4. Belperio PS1, Hwang EW, Thomas IC, Mole LA, Cheung RC, Backus LI. Early virologic responses and hematologic safety of direct- acting antiviral therapies in veterans with chronic hepatitis C. Clin Gastroenterol Hepatol 2013; 11(8): 1021-7.

  5. Strasser SI, Myerson D, Spurgeon CL, Sullivan KM, Storer B, Schoch HG, Kim S, et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10- year follow-up. Hepatology 1999; 29(6): 1893-9.

  6. Ljungman P, Locasciulli A, de Soria VG, Békássy AN, Brinch L, Espigado I, Ferrant A, et al. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Long-term follow-up of HCV- infected hematopoietic SCT patients and effects of antiviral therapy. Bone Marrow Transplant 2012; 47: 1217-21.

  7. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Retrieved from: http://www.hcvguidelines.org/fullreport- view 2014.

  8. Mutimer D, Aghemo A, Diepolder H, Negro F, Robaeys G, Ryder S, Zoulim F, et al. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. European Association for Study of Liver. J Hepatol 2014; 60: 392-420.




2020     |     www.medigraphic.com